Easyhaler® in Asthma Guidelines
Product info | 01/12/2020
Prescribing information and Adverse event reporting can be found at the bottom of this page.
ONE DEVICE AT EVERY STEP OF THE BTS / SIGN 2019
ASTHMA GUIDELINES1
WITH THE EASYHALER® RANGE, YOU CAN:
- Prescribe a low dose ICS for new patients (aged 6 years and over) with Easyhaler Budesonide (budesonide).2
- Prescribe a range of drug therapies within the Easyhaler® range and have the flexibility to move patients across the BTS / SIGN guidelines to find and maintain the lowest controlling therapy1
- Provide initial add on therapy with Fobumix Easyhaler (budesonide / formoterol fumarate dihydrate) (adults only)
Download your "Easyhaler and The Guidelines"
|
Easyhaler® Budesonide Indication: Treatment of mild, moderate or severe persistent asthma. Note: Easyhaler® Budesonide is not suitable for the treatment of acute asthma attacks.
Fobumix Easyhaler® Indication: Asthma all strengths: Indicated in adults (18 years and older) for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting ß2 adrenoceptor agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ß2 adrenoceptor agonists or patients already adequately controlled on both inhaled corticosteroids and long-acting ß2 adrenoceptor agonists.
Note: Fobumix Easyhaler® 80mcg/4.5mcg is not appropriate in patients with severe asthma.
Was this article helpful?
REFERENCES:
- BTS/SIGN. British guidelines on the Management of Asthma - a national clinical guideline. SIGN 158 Revised July 2019. https://www.britthoracic.org.uk/qualityimprovement/guidelines/asthma/
- Easyhaler® Budesonide SmPC, 100mcg, 200mcg, 400mcg. Orion Pharma.
- Fobumix Easyhaler® SmPC, 80/4.5mcg, 160/4.5mcg, 320/9mcg. Orion Pharma
BTS / SIGN = British Thoracic Society / Scottish Intercollegiate Guidelines Network
ICS = Inhaled Corticosteroids, SmPC = Summary of Product Characteristics
DPI = Dry powder inhalers
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Orion Pharma (UK) Ltd
on 01635 520300.
August 2024 / RESP-330bbf(3)
Full prescribing information available here
OCTOBER 2023 / RESP-330B(9)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300.
